Year-end Sale % OFF 
Abstract
Meeting abstracts OX40, a member of the Tumor Necrosis Factor Receptor superfamily is a potent co-stimulatory molecule. OX40 engagement increases T cell proliferation, effector function and survival. Pre-clinical studies have shown that OX40 agonist synergizes with radiation and cyclophosphamide to
Highlights
OX40, a member of the Tumor Necrosis Factor Receptor superfamily is a potent co-stimulatory molecule
The immunological analysis was performed on peripheral blood lymphocytes (PBL) using a multi-color flow analysis panel containing CD3, CD4, CD8, CD95, CD25, CD38, HLA-DR and the intracellular markers, FoxP3 and Ki-67
The immunological response measured in the PB shows a 2-3.5-fold increase in the proliferating CD4+ CD95+ T cells, mostly in the FoxP3- population
Summary
Phase I/II clinical trial of anti-OX40, radiation and cyclophosphamide in patients with prostate cancer: immunological analysis. Magdalena Kovacsovics-Bankowski*, Lana Chisholm, Jonna Vercellini, Marka Crittenden, Scot Lary, Brendan Curti, Andrew Weinberg. From Society for Immunotherapy of Cancer 28th Annual Meeting National Harbor, MD, USA. From Society for Immunotherapy of Cancer 28th Annual Meeting National Harbor, MD, USA. 8-10 November 2013
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
